The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms

J. D. Robinson, C. Y. Lam, J. A. Minnix, D. W. Wetter, G. E. Tomlinson, J. D. Minna, T. T.L. Chen, P. M. Cinciripini

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


The dopamine receptor D2 (DRD2) gene has polymorphisms that have been linked to regulation of the dopamine system and to an increased prevalence of smoking. The present study examined the relationship of the DRD2 TaqI-A and -B polymorphisms with short-term clinical outcome (abstinence and withdrawal symptoms), collected from daily (14 pre-quit and 42 post-quit) diary data among smokers (n=116) treated with the nicotine patch plus either venlafaxine or placebo. The results showed that B1/B1 or B1/B2 smokers were slightly less likely to be abstinent on a given day than those homozygous for the TaqI-B2 allele. Significant DRD2 TaqI-B × time interactions were found for several of the withdrawal scales, indicating that those smokers with the B1/B1 or B1/B2 genotypes tended to report more symptoms over time compared to those with the B2/B2 genotype. No interactions or main effects were found for the DRD2 TaqI-A polymorphism. The findings demonstrate that smokers homozygous for the TaqI-B2 allele experience progressive improvement in self-reported withdrawal symptoms while smokers with the TaqI-B1 allele showing little change.

Original languageEnglish (US)
Pages (from-to)266-274
Number of pages9
JournalPharmacogenomics Journal
Issue number4
StatePublished - Aug 2007

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms'. Together they form a unique fingerprint.

Cite this